Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

S. Rule, W. Jurczak, M. Jerkeman, C. Rusconi, M. Trneny, F. Offner, D. Caballero, C. Joao, M. Witzens-Harig, G. Hess, I. Bence-Bruckler, SG. Cho, C. Thieblemont, W. Zhou, T. Henninger, J. Goldberg, J. Vermeulen, M. Dreyling,

. 2018 ; 32 (8) : 1799-1803. [pub] 20180202

Language English Country England, Great Britain

Document type Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19028507
E-resources Online Full text

NLK ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Nursing & Allied Health Database (ProQuest) from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago
Public Health Database (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 29572505
DOI 10.1038/s41375-018-0023-2
Knihovny.cz E-resources

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028507
003      
CZ-PrNML
005      
20190815105434.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-018-0023-2 $2 doi
035    __
$a (PubMed)29572505
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rule, S $u Plymouth University Medical School, Plymouth, UK. Simon.Rule@nhs.net.
245    10
$a Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study / $c S. Rule, W. Jurczak, M. Jerkeman, C. Rusconi, M. Trneny, F. Offner, D. Caballero, C. Joao, M. Witzens-Harig, G. Hess, I. Bence-Bruckler, SG. Cho, C. Thieblemont, W. Zhou, T. Henninger, J. Goldberg, J. Vermeulen, M. Dreyling,
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mezinárodní agentury $7 D007390
650    _2
$a lymfom z plášťových buněk $x farmakoterapie $x patologie $7 D020522
650    _2
$a prognóza $7 D011379
650    _2
$a pyrazoly $x aplikace a dávkování $7 D011720
650    _2
$a pyrimidiny $x aplikace a dávkování $7 D011743
650    12
$a záchranná terapie $7 D016879
650    _2
$a sirolimus $x aplikace a dávkování $x analogy a deriváty $7 D020123
650    _2
$a míra přežití $7 D015996
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jurczak, W $u Department of Hematology, Jagiellonian University, Krakow, Poland.
700    1_
$a Jerkeman, M $u Skånes University Hospital, Lund University, Lund, Sweden.
700    1_
$a Rusconi, C $u Hematology Division, Hematology and Oncology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
700    1_
$a Trneny, M $u Ist Dept Medicine, Charles University General Hospital, Prague, Czech Republic.
700    1_
$a Offner, F $u Departement Oncologie, UZ Gent, Ghent, Belgium.
700    1_
$a Caballero, D $u Instituto Biosanitario de Salamanca, Hospital Clinico Universitario Salamanca, Salamanca, Spain.
700    1_
$a Joao, C $u Institutto Português de Oncologia de Lisboa, Portugal and Champalimaud Centre for the Unknown, Hematology, Lisbon, Portugal.
700    1_
$a Witzens-Harig, M $u Klinikum der Ruprechts-Karls-Universität Heidelberg, Med. Klinik u. Poliklinik V, Heidelberg, Germany.
700    1_
$a Hess, G $u Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University, Mainz, Germany.
700    1_
$a Bence-Bruckler, I $u The Ottawa Hospital, General Campus, Ottawa, ON, Canada.
700    1_
$a Cho, S-G $u Seoul St. Mary's Hospital, Seocho-gu, Seoul, South Korea.
700    1_
$a Thieblemont, C $u APHP, Saint-Louis Hospital, Hemato-oncology, Diderot University, Paris, France.
700    1_
$a Zhou, W $u Janssen Research & Development, Raritan, NJ, USA.
700    1_
$a Henninger, T $u Janssen Research & Development, Raritan, NJ, USA.
700    1_
$a Goldberg, J $u Janssen Research & Development, Raritan, NJ, USA.
700    1_
$a Vermeulen, J $u Janssen Research & Development, Leiden, The Netherlands.
700    1_
$a Dreyling, M $u Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany.
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 32, č. 8 (2018), s. 1799-1803
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29572505 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190815105702 $b ABA008
999    __
$a ok $b bmc $g 1433656 $s 1066967
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 32 $c 8 $d 1799-1803 $e 20180202 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Archiving options